• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: July 7, 2025

Key Takeaways

  • Whole-body cryotherapy shows potential as a non-pharmacologic treatment for atopic dermatitis, offering inflammation relief.
  • APG777, an anti-IL-13 antibody, demonstrates high efficacy in moderate to severe atopic dermatitis, achieving significant EASI-75 response rates.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Cold Therapy May Relieve Inflammation in AD

Explore the potential of whole-body cryotherapy as a novel, non-pharmacologic treatment for managing atopic dermatitis symptoms effectively.

APG777 Demonstrates High EASI-75 Response Rates in Moderate to Severe Atopic Dermatitis

New 16-week data from the phase 2 APEX clinical trial demonstrated the anti-IL-13 antibody's efficacy across all key endpoints.

Laser Therapy Gains Ground in Acne Management

Discover the latest advancements in laser treatments for acne vulgaris, focusing on diverse skin types and effective solutions for acne skin of color.

VYNE Unblinds Early VYN202 Data After Safety Pause

VYNE Therapeutics updates on VYN202, revealing promising early results in psoriasis treatment despite a clinical hold due to safety concerns.

Dermatology Times' Weekly Crossword: July 7, 2025

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Beyond the Label: Evaluating Bimekizumab’s Mental Health Profile in Psoriasis Treatment

Although bimekizumab carries a precaution for suicidal ideation and behavior, current data suggest it may improve mental health outcomes for patients with psoriasis.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.